Molecular Pharmacology and Oncology
The desire to overcome cancer is one that is shared by the entire world: Indeed, cancer is one of the most critical contemporary issues in global health. Efforts are being advanced in Japan to combat cancer on the national level, and “Cancer professionals promoting program” of The Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) led us to close Department of Molecular and Cellular Pharmacology and reformed to Department of Molecular Pharmacology and Oncology (DMPO), which aim to realize cancer medical innovation. The Department of Molecular Pharmacology and Oncology is home to research focused on (1) understanding biology of cancer to discover novel medical seeds, (2) understanding the mechanism of drug actions, (3) developing new molecular diagnostics and (3) developing new cancer therapeutics including drug discovery and personalized medicine. The DMPO offers a broad range of medical and basic research topics to be high-level professionals to take leadership roles in the field of cancer pharmacology, as well as active international roles.
|Associate Professor||Susumu ROKUDAI,Ph.D.|
|Assistant Professor||Katsuyo SAITO, Ph.D.|
Research & Education
Main research subjects ongoing are as follows,
1. Molecular Cancer Biology
2. Molecular Pharmacology and Cancer Drug discovery based on Omics Science
3. Development of Predictive Biomarkers of Anticancer Drug Therapy for Precision Medicine.
4. Development of Novel Diagnostics for Cancer
5. Tumor Resistance to Anticancer Therapies and its overcome
6. Microenvironment, Metabolism, and Cancer
7. Molecular Biology of Benign Disease
●Graduate School of Medicine
1. Molecular Pharmacology and Oncology (Lecture, Seminar, Technical course, etc.)
2. Cancer Biology and Development of Therapeutics and Diagnostics for Cancer (Seminar, Technical course, etc.)
3. Cancer Professionals Promoting Program (Clinical study and Biostatistics, Medical ethics and Regulations, Basic Oncology, Psycho-Social Oncology and Patient Education, Cancer Care and Care Team, etc.)
4. Molecular Pharmacology and Oncology (Methodology, Research, etc.)
●School of Medicine
5. Pharmacology (Lecture and laboratory Practice)
6. Selective Laboratory Training
(no clinical assignments)
1. Rokudai S, Li Y, Otaka Y, Fujieda M, Owens D, Christiano A, Nishiyama M, Prives C. STXBP4 Regulates APC/C-Mediated p63 Turnover and Drives Squamous Cell Carcinogenesis. Proc Natl Acad Sci U S A. 2018 May 22;115(21):E4806-E4814. doi: 10.1073/pnas.1718546115.
2. Arai H, Nobusawa S, Kawabata-Iwakawa R, Rokudai S, Higuchi T, Yamazaki T, Horiguchi J, Sano T, Kojima M, Nishiyama M, Yokoo H, Hirato J, Oyama T. Myeloid sarcoma arising in malignant phyllodes tumour: clonal relationships revealed by comparative genome-wide analyses. Br J Haematol. 2018 Apr;181(2):255-259. doi: 10.1111/bjh.14539.
3. Blomme A, Van Simaeys G, Doumont G, Costanza B, Bellier J, Otaka Y, Sherer F, Lovinfosse P, Boutry S, Palacios A, De Pauw E, Hirano T, Yokobori T, Hustinx R, Bellahcene A, Delvenne P, Detry O, Goldman S, Nishiyama M, Castronovo V, turtoi A. Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases. Oncogene. 2018 Mar;37(9):1237-1250. doi: 10.1038/s41388-017-0018-x.
4. Costanza B, Turtoi A, Bellahcène A, Hirano T, Peulen O, Blomme A, Hennequière V, Mutijima E, Boniver J, Meuwis MA, Josse C, Koopmansch B, Segers K, Yokobori T, Fahmy K, Thiry M, Coimbra C, Garbacki N, Colige A, Baiwir D1,11, Bours V, Louis E, Detry O, Delvenne P, Nishiyama M, Castronovo V. Innovative methodology for the identification of soluble biomarkers in fresh tissues. Oncotarget. 2018 Jan 31;9(12):10665-10680. doi: 10.18632/oncotarget.24366. eCollection 2018 Feb 13.
5. Kaira K, Higuchi T, Naruse I, Arisaka Y, Altan B, Mogi A, Shimizu K, Sunaga N, Hisada T, Kitano S, Obinata H, Yokobori T, Mori K, Nishiyama M, Tsushima Y, Asao T. Metabolic activity by 18F-FDG-PET/CT is predictive for early response after nivolumab in previously treated NSCLC. Eur J Nucl Med. Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):56-66. doi: 10.1007/s00259-017-3806-1.
6. Kumakura Y, Rokudai S, Iijima M, Altan B, Yoshida T, Bao H, Yokobori T, Sakai M, Sohda M, Miyazaki T, Nishiyama M, Kuwano H. Elevated Expression of ΔNp63 in Advanced Esophageal Squamous Cell Carcinoma. Cancer Sci. 2017 Nov;108(11):2149-2155. doi: 10.1111/cas.13394.
7. Bai T, Yokobori T, Altan B, Ide M, Mochiki E, Yanai M, Kimura A, Kogure N, Yanoma T, Suzuki M, Bao P, Kaira K, Asao T, Katayama A, Handa T, Gombodorj N, Nishiyama M, Oyama T, Ogata K, Kuwano H. High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients. Br J Cancer. 2017 Apr 25;116(9):1177-1185. doi: 10.1038/bjc.2017.76.
8. Tsukagoshi M, Araki K, Yokobori T, Altan B, Suzuki H, Kubo N, Watanabe A, Ishii N, Hosouchi Y, Nishiyama M, Shirabe K, Kuwano H. Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitibity vianuckear translocation of DNA repair proteins. Oncotarget. 2017 Jun 27;8(26):42159-42172. doi: 10.18632/oncotarget.15020.
9. Otaka Y, Rokudai S, Kaira K, Fujieda M, Horikoshi I, Kawabara R, Yoshiyama S, Yokobori T, Ohtaki Y, Shimizu K, Oyama T, Tamura J, Prives C, Nishiyama M. STXBP4 drives tumor growth and is associated with poor prognosis through PDGF Receptor signaling in lung squamous cell carcinoma. Clin Cancer Res. 2017 Jul 1;23(13):3442-3452. doi: 10.1158/1078-0432.CCR-16-1815.
10. Igarashi T, Araki K, Yokobori T, Altan B, Yamanaka T, Ishii N, Tsukagoshi M, Watanabe A, Kubo N, Handa T, Hosouchi Y, Nishiyama M, Oyama T, Shirabe K, Kuwano H. Association of RAB5 overexpression in pancreatic cancer with cancer progression and poor prognosis via E-cadherin suppression. Oncotarget. 2017 Feb 14;8(7):12290-12300. doi: 10.18632/oncotarget.14703.
11. Blomme A, Costanza B, de Tullio P, Thiry M, Van Simaeys G, Boutry S, Doumont G, Di Valentin E, Hirano T, Yokobori T, Gofflot S, Peulen O, Bellahcène A, Sherer F, Le Goff C, Cavalier E, Mouithys-Mickalad A, Jouret F, Cusumano PG, Lifrange E, Muller RN, Goldman S, Delvenne P, De Pauw E, Nishiyama M, Castronovo V, Turtoi A. Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer. Oncogene. 2017 Apr;36(15):2116-2130. doi: 10.1038/onc.2016.369.
12. George J, Saito M, Tsuta K, Iwakawa R, Shiraishi K, Scheel AH, Uchida S, Watanabe SI, Nishikawa R, Noguchi M, Peifer M, Jang SJ, Petersen I, Büttner R, Harris CC, Yokota J, Thomas RK, Kohno T. Genomic Amplification of CD274 (PD-L1) in Small-Cell Lung Cancer. Clin Cancer Res. 2017 Mar 1;23(5):1220-1226. doi: 10.1158/1078-0432.CCR-16-1069.
13. Tsuboi M, Yamane A, Horiguchi J, Yokobori T, Kawabata-Iwakawa R, Yoshiyama S, Rokudai S, Odawara H, Tokiniwa H, Oyama T, Takeyoshi I, Nishiyama M. APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers. Breast Cancer. 2016 Sep;23(5):780-8. doi: 10.1007/s12282-015-0641-8.
14. Takahashi H, Sakakura K, Kawabata-Iwakawa R, Rokudai S, Toyoda M, Nishiyama M, Chikamatsu K. Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma. Cancer Immunol Immunother. 2015 Nov;64(11):1407-17. doi: 10.1007/s00262-015-1742-0.
15. Simó-Riudalbas L, Pérez-Salvia M, Setien F, Villanueva A, Moutinho C, Martínez-Cardús A, Moran S, Berdasco M, Gomez A, Vidal E, Soler M, Heyn H, Vaquero A, de la Torre C, Barceló-Batllori S, Vidal A, Roz L, Pastorino U, Szakszon K, Borck G, Moura CS, Carneiro F, Zondervan I, Savola S, Iwakawa R, Kohno T, Yokota J, Esteller M. KAT6B Is a Tumor Suppressor Histone H3 Lysine 23 Acetyltransferase Undergoing Genomic Loss in Small Cell Lung Cancer. Cancer Res. 2015 Sep 15;75(18):3936-45. doi: 10.1158/0008-5472.CAN-14-3702.
16. Teng G, Maman Y, Resch W, Kim M, Yamane A, Qian J, Kieffer-Kwon KR, Mandal M, Ji Y, Meffre E, Clark MR, Cowell LG, Casellas R, Schatz DG. RAG Represents a Widespread Threat to the Lymphocyte Genome. Cell. 2015 Aug 13;162(4):751-65. doi: 10.1016/j.cell.2015.07.009.
17. George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015 Aug 6;524(7563):47-53. doi: 10.1038/nature14664.
18. Romero OA, Torres-Diz M, Pros E, Savola S, Gomez A, Moran S, Saez C, Iwakawa R, Villanueva A, Montuenga LM, Kohno T, Yokota J, Sanchez-Cespedes M.: MAX inactivation in small-cell lung cancer disrupts the MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discov. 2014 Mar;4(3):292-303. doi: 10.1158/2159-8290.CD-13-0799.
19. Kieffer-Kwon KR, Tang Z, Mathe E, Qian J, Sung MH, Li G, Resch W, Baek S, Pruett N, Grøntved L, Vian L, Nelson S, Zare H, Hakim O, Reyon D, Yamane A, Nakahashi H, Kovalchuk AL, Zou J, Joung JK, Sartorelli V, Wei CL, Ruan X, Hager GL, Ruan Y, Casellas R. Interactome maps of mouse gene regulatory domains reveal basic principles of transcriptional regulation. Cell. 2013 Dec 19;155(7):1507-20. doi: 10.1016/j.cell.2013.11.039.
20. Rokudai S., Laptenko O., Arnal SM., Taya Y., Kitabayashi I., Prives C.: MOZ increases p53 acetylation and premature senescence through its complex formation with PML. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3895-900. doi: 10.1073/pnas.1300490110.
2012 Dr. Masahiko NISHIYAMA became the professor, director of Department of Molecular Pharmacology and Oncology
Cancer professionals promoting program of The Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT) led us to reorganize Department of Molecular and Cellular Pharmacology as Department of Molecular Pharmacology and Oncology. The new department offers a broad range of medical and basic research including translational research that facilitates the translation of findings from basic science- cancer biology, molecular oncology, and cancer pharmacology- to practical applications that enhance human health and well-being.
1989 Dr. Kazuhiro KOHAMA became the professor, director of Department of Molecular and Cellular Pharmacology
Base on the acquaintances that understanding of signal transduction mechanisms is indispensable in pharmacology, biological regulation mechanism of calcium ion, especially on myosin was studied as main research subject.
1975 Dr. Kunihiko OBATA became the professor, director of Department of Pharmacology: Under him, the developmental study on central nerve system was started. The main subjects of researches were (1) identification of the substances in the “conditioning medium” and (2) determination of marker proteins of differentiation of nervous system. Dr. Tanaka studied an adhesion molecule of motor nerve to be nominated as a professor of Kumamoto University. Dr. Shirao, current professor of Neurobiology and behavior of Gunma University, found a protein specific for brain development, drebin.
1943 Department of Pharmacology was first opened as a key department of Maebashi Medical College, a parent school of Gunma University, and Dr. Katsuhiro SHIBATA was appointed Professor and performed researches focusing on endocrine pharmacology, especially for adrenocorticosteroid, and toxicology of heavy metals. He promoted Dr. Takeuchi to as professor of the Nippon medical School, and Dr. Tadokoro to as professor of the Institute of Behavioral Science, Gunma University.